medigraphic.com
ISSN 1527-3172 (Digital)

2021, Número 3-4

<< Anterior Siguiente >>

MEDICC Review 2021; 23 (3-4)


Subtype-Dependent Co-receptor Tropism in Cuban HIV-1–Infected Patients: Implications for Maraviroc Treatment

Martínez-Montesino Y, Kourí-Cardellá V, Pérez-Santos L, Han R, Pintos-Saavedra Y, Alemán-Campos Y, Soto-Brito Y, Baños-Morales Y, Caturla-Fernández Y

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 29-36
Archivo PDF: 399.82 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Riemenschneider M, Cashin KY, Budeus B,Sierra S, Shirvani-Dastgerdi E, BayanolhaghS, et al. Genotypic Prediction of Co-receptorTropism of HIV-1 Subtypes A and C. Sci Rep[Internet]. 2016 [cited 2020 Dec 3];6:24883.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850382/pdf/srep24883.pdf

  2. Pérez-Álvarez L, Delgado E, Vega Y, MonteroV, Cuevas T, Fernández-García A, et al.Predominance of CXCR4 tropism in HIV-1 CRF14_BG strains from newly diagnosedinfections. J Antimicrob Chemother [Internet].2014 Jan [cited 2020 Dec 2];69(1):246–53.Available at: https://pdfs.semanticscholar.org/3ada/c6787c3af51dfa8b2b51764550cfe6f57608.pdf?_ga=2.176869410.60519488.1608083556-726339794.1548872336

  3. Soulie C, Morand-Joubert L, Cottalorda J,Charpentier C, Bellecave P, Le Guen L, et al.Performance of genotypic algorithms for predictingtropism for HIV-1 CRF01_AE recombinant. J ClinVirol [Internet]. 2018 Feb–Mar [cited 2020 Dec2];99–100:57–60. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(17)30354-2

  4. Panos G, Watson DC. Effect of HIV-1 subtype andtropism on treatment with chemokine coreceptorentry inhibitors; overview of viral entry inhibition.Crit Rev Microbiol [Internet]. 2015 [cited 2020Dec 2];41(4):473–87. Available at: https://www.tandfonline.com/doi/full/10.3109/1040841X.2013.867829?scroll=top&needAccess=true

  5. Woollard SM, Kanmogne GD. Maraviroc: a reviewof its use in HIV infection and beyond. Drug DesDevel Ther [Internet]. 2015 Oct 1 [cited 2020 Dec2];9:5447–68. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26491256/

  6. Schuitemaker H, van ‘t Wout AB, Lusso P.Clinical signifi cance of HIV-1 coreceptor usage.J Transl Med [Internet]. 2011 Jan 27 [cited 2020Dec 15];9 Suppl 1 (Suppl 1):S5. Available at:https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-S1-S5

  7. Mild M, Esbjornsson J, Fenyo EM, MedstrandP. Frequent intrapatient recombination betweenhuman immunodefi ciency virus type 1 R5 andX4 envelopes: implications for coreceptor switch.J Virol [Internet]. 2007 Apr [cited 2020 Dec16];81(7):3369–76. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1866041/pdf/1295-06.pdf

  8. Phuphuakrat A, Phawattanakul S, Pasomsub E,Kiertiburanakul S, Chantratita W, SungkanuparphS. Coreceptor tropism determined by genotypicassay in HIV-1 circulating in Thailand, whereCRF01_AE predominates. HIV Med [Internet].2014 May [cited 2020 Dec 15];15(5):269–75.Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.12108

  9. Asin-Milan O, Chamberland A, Wei Y, HaidaraA, Sylla M, Tremblay CL. Mutations in variabledomains of the HIV-1 envelope gene can havea signifi cant impact on maraviroc and vicrivirocresistance. AIDS Res Ther [Internet]. 2013 Jun 7[cited 2020 Dec 20];10(1):15. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700831/pdf/1742-6405-10-15.pdf

  10. Recordon-Pinson P, Soulie C, Flandre P, DescampsD, Lazrek M, Charpentier C, et al. Evaluation ofthe genotypic prediction of HIV-1 coreceptor useversus a phenotypic assay and correlation withthe virological response to maraviroc: the ANRSGenoTropism study. Antimicrob Agents Chemother[Internet]. 2010 Aug [cited 2020 Dec 3];54(8):3335–40. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916345/pdf/0148-10.pdf

  11. Poveda E, Alcami J, Paredes R, CórdobaJ, Gutiérrez F, Llibre JM, et al. Genotypicdetermination of HIV tropism - clinical andmethodological recommendations to guide thetherapeutic use of CCR5 antagonists. AIDS Rev[Internet]. 2010 [cited 2020 Dec18];12(3):135–48. Available at: https://www.researchgate.net/publication/230569071_Genotypic_Determination_of_HIV_TropismClinical_and_methodological_recommendations_to_guide_the_therapeutic_use_of_CCR5_antagonists/link/00b4952ea736ab0cf1000000/download

  12. Dina J, Raymond S, Maillard A, Le Guillou-Guillemette H, Rodalec A, Beby-Defaux A, etal. Algorithm-based prediction of HIV-1 subtypeD coreceptor use. J Clin Microbiol [Internet].2013 Sep [cited 2020 Dec 15];51(9):3087–9.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754628/pdf/zjm3087.pdf

  13. Angel JB, Saget BM, Walsh SP, Greten TF,Dinarello CA, Skolnik PR, et al. Rolipram, aspecifi c type IV phosphodiesterase inhibitor,is a potent inhibitor of HIV-1 replication. AIDS[Internet]. 1995 Oct [cited 2020 Dec 16];9(10):1137–44. Available at: https://journals.lww.com/AIDSonline/Abstract/1995/10000/Rolipram,_a_specifi c_type_IV_phosphodiesterase.4.aspx

  14. Borthwick NJ, Bofi ll M, Gombert WM, Akbar AN,Medina E, Sagawa K, et al. Lymphocyte activationin HIV-1 infection. II. Functional defects of CD28-T cells. AIDS [Internet]. 1994 Apr [cited 2020Dec 2];8(4):431–42. Available at: https://journals.lww.com/AIDSonline/Abstract/1994/04000/Lymphocyte_activation_in_HIV_1_infection__II_.4.aspx

  15. Kourí V, Khouri R, Alemán Y, Abrahantes Y,Vercauteren J, Pineda-Pena AC, et al. CRF19_cpx is an evolutionary fi t HIV-1 variant stronglyassociated with rapid progression to AIDS inCuba. EBioMedicine [Internet]. 2015 Jan 28[cited 2020 Dec 16];2(3):244–54. Availableat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484819/pdf/main.pdf

  16. Pérez L, Kouri V, Alemán Y, Abrahantes Y,Correa C, Aragones C, et al. Antiretroviral drugresistance in HIV-1 therapy-naive patients inCuba. Infect Genet Evol [Internet]. 2013 Jun[cited 2020 Dec 15];16:144–50. Available at:https://www.sciencedirect.com/science/article/abs/pii/S1567134813000361

  17. Fenyö EM, Esbjörnsson J, Medstrand P,Jansson M. Human immunodefi ciency virustype 1 biological variation and coreceptoruse: from concept to clinical signifi cance. JIntern Med [Internet]. 2011 Dec [cited 2020Dec 17];270(6):520–31. Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2796.2011.02455.x

  18. Kourí V, Alemán Y, Díaz D, Pérez L, Limia CM,Soto Y, et al. Co-receptor tropism determinedby genotypic assay in HIV-1 circulating inCuba. J AIDS Clin Res [Internet]. 2016 [cited2020 Dec 2];7(7):592. Available at: https://www.hilarispublisher.com/open-access/coreceptor-tropism-determined-by-genotypic-assay-in-hiv1-circulating-in-cuba-2155-6113-1000592.pdf

  19. Kourí V, Alemán Y, Pérez L, Pérez J, FonsecaC, Correa C, et al. High frequency of antiviraldrug resistance and non-B subtypes in HIV-1patients failing antiviral therapy in Cuba. J ClinVirol [Internet]. 2012 Dec 5 [cited 2020 Dec2];55(4):348–55. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225368/pdf/JIAS-17-19754.pdf

  20. Pineda-Pena AC, Faria NR, Imbrechts S, LibinP, Abecasis AB, Deforche K, et al. Automatedsubtyping of HIV-1 genetic sequences for clinicaland surveillance purposes: performance evaluationof the new REGA version 3 and seven other tools.Infect Genet Evol [Internet]. 2013 Oct [cited 2020Dec 14];19:337–48. Available at: https://reader.elsevier.com/reader/sd/pii/S1567134813001810?token=224CF28032AD88B452AD006B04DDF3EEA3E86330D469FD9040A10BEC8BE99E5839D54348182D867AB69D2307C8D37009

  21. de Oliveira T, Deforche K, Cassol S, SalminenM, Paraskevis D, Seebregts C, et al. Anautomated genotyping system for analysisof HIV-1 and other microbial sequences.Bioinformatics [Internet]. 2005 Oct 1 [cited 2020Dec 16];21(19):3797–800. Available at: https://www.researchgate.net/publication/7682559_An_automated_genotyping_system_for_analysis_of_HIV-1_and_other_microbial_sequences

  22. Lemoine F, Correia D, Lefort V, Doppelt-Azeroual O, Mareuil F, Cohen-Boulakia S, et al.NGPhylogeny.fr: new generation phylogeneticservices for non-specialists. Nucleic AcidsRes [Internet]. 2019 Apr 27 [cited 2020 Dec3];47(W1):W260–W5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602494/pdf/gkz303.pdf

  23. Alemán Y, Vinken L, Kouri V, Pérez L, ÁlvarezA, Abrahantes Y, et al. Performance of anin-house human immunodefi ciency virus type1 genotyping system for assessment of drugresistance in Cuba. PLoS One [Internet]. 2015Feb 11 [cited 2020 Dec 14];10(2):e0117176.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324769/pdf/pone.0117176.pdf

  24. Lengauer T, Sander O, Sierra S, Thielen A, KaiserR. Bioinformatics prediction of HIV coreceptorusage. Nat Biotechnol [Internet]. 2007 Dec[cited 2020 Dec 4];25(12):1407–10. Available at:https://www.nature.com/articles/nbt1371

  25. Jensen MA, van ‘t Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis.AIDS Rev [Internet]. 2003 Apr–Jun [cited2020 Dec 4];5(2):104–12. Available at: https://www.researchgate.net/publication/10648055_Predicting_HIV1_coreceptor_usage_with_sequence_analysis

  26. Seclén E, Garrido C, González M M, González-Lahoz J, de Mendoza C, Soriano V, et al. Highsensitivity of specifi c genotypic tools for detectionof X4 variants in antiretroviral-experiencedpatients suitable to be treated with CCR5antagonists. J Antimicrob Chemother [Internet].2010 Jul [cited 2020 Dec 16];65(7):1486–92.Available at: https://www.researchgate.net/publication/43351431_High_sensitivity_of_specific_genotypic_tools_for_detection_of_X4_variants_in_antiretroviralexperienced_patients_suitable_to_be_treated_with_CCR5_antagonists

  27. Fogel GB, Lamers SL, Liu ES, Salemi M,McGrath MS. Identifi cation of dual-tropic HIV-1 using evolved neural networks. Biosystems[Internet]. 2015 Nov [cited 2020 Dec 3];137:12–9.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921197/pdf/nihms730074.pdf

  28. Matume ND, Tebit DM, Gray LR, HammarskjoldML, Rekosh D, Bessong PO. Next generationsequencing reveals a high frequency of CXCR4utilizing viruses in HIV-1 chronically infecteddrug experienced individuals in South Africa. JClin Virol [Internet]. 2018 Jun [cited 2020 Dec17];103:81–7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229640/pdf/nihms-1584881.pdf

  29. Hayashida T, Tsuchiya K, Kikuchi Y, Oka S,Gatanaga H. Emergence of CXCR4-tropicHIV-1 variants followed by rapid diseaseprogression in hemophiliac slow progressors.PLoS One [Internet]. 2017 May 4 [cited 2020 Dec16];12(5):e0177033. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417636/pdf/pone.0177033.pdf

  30. Gupta S, Neogi U, Srinivasa H, Banerjea AC,Shet A. HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtypeC strains over two decades. J Acquir ImmuneDefi c Syndr [Internet]. 2014 Apr 1 [cited 2020 Dec17];65(4):397–404. Available at: https://journals.lww.com/jAIDS/Fulltext/2014/04010/HIV_1_Coreceptor_Tropism_in_India Increasing.3.aspx

  31. Guo JL, Yan Y, Zhang JF, Ji JM, Ge ZJ, GeR, et al. Co-receptor tropism and geneticcharacteristics of the V3 regions in variantsof antiretroviral-naive HIV-1 infected subjects[Internet]. Epidemiol Infect. 2019 Jan [cited 2020Dec 18];147:e181. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518647/pdf/S0950268819000700a.pdf

  32. Morgado MG, Guimaraes ML, Gripp CB,Neves Junior I, Costa CI, dos Santos VG, et al.Polymorphism of the predictive antigenic sites onthe V3 loop of Brazilian HIV-1 subtype B strains.HEC/FIOCRUZ AIDS Clinical Research Group.Mem Inst Oswaldo Cruz [Internet]. 1996 May–Jun [cited 2020 Dec 18];91(3):339–42. Availableat: https://www.scielo.br/pdf/mioc/v91n3/15.pdf

  33. Milich L, Margolin BH, Swanstrom R. Patternsof amino acid variability in NSI-like and SI-likeV3 sequences and a linked change in theCD4-binding domain of the HIV-1 Env protein.Virology [Internet]. 1997 Dec 8 [cited 2020Dec 18];239(1):108–18. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0042-6822(97)98821-8

  34. Heera J, Valluri SR, Craig C, Fang A, ThomasN, Meyer RD, et al. First prospective comparisonof genotypic versus phenotypic tropism assays inpredicting virologic responses to maraviroc in aphase 3 study. New Microbiol [Internet]. 2019 Apr[cited 2020 Dec 19];41(2):101–7. Available at:http://www.newmicrobiologica.org/PUB/allegati_pdf/2019/2/101.pdf

  35. Esbjörnsson J, Månsson F, Martínez-Arias W,Vincic E, Biague AJ, da Silva ZJ, et al. FrequentCXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of anevolving epidemic in West Africa. Retrovirology[Internet]. 2010 Mar 22 [cited 2020 Dec 18];7:23.DOI: 10.1186/1742-4690-7-23. Available at:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855529/pdf/1742-4690-7-23.pdf

  36. Church JD, Huang W, Mwatha A, Toma J, Stawiski E,Donnell D, et al. HIV-1 tropism and survival in verticallyinfected Ugandan infants. J Infect Dis [Internet].2008 May 15 [cited 2020 Dec 18];197(10):1382–8.Available at: https://pdfs.semanticscholar.org/be30/beae653aaaea6cd4305dd42ae01d7232364d.pdf?_ga=2.8524978.60519488.1608083556-726339794.1548872336




2020     |     www.medigraphic.com